Section Arrow
AAPG.NASDAQ
- Ascentage Pharma Group
Quotes are at least 15-min delayed:2025/09/13 22:58 EDT
Regular Hours
Last
 40.46
+0.57 (+1.43%)
Day High 
40.7 
Prev. Close
39.89 
1-M High
48.45 
Volume 
9.66K 
Bid
40.41
Ask
40.66
Day Low
40 
Open
40.02 
1-M Low
38 
Market Cap 
3.71B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 40.59 
20-SMA 42.88 
50-SMA 41.01 
52-W High 48.45 
52-W Low 16.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-14.52/--
Enterprise Value
4.60B
Balance Sheet
Book Value Per Share
1.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
221.98M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
COCPCocrystal Pharma1.58+0.14+9.72%-- 
ADAPAdaptimmune Therapeutics plc0.056+0.0055+10.89%-- 
PLRZPolyrizon Ltd1.2+0.2225+22.76%-- 
MRNAModerna23.51-1.88-7.40%-- 
HCWBHCW Biologics Inc5.59+2.27+68.37%-- 
Quotes are at least 15-min delayed:2025/09/13 22:58 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.